Special Issue

Novel Biomarkers in the Diagnostics of Cancer

Message from the Guest Editors

This Special Issue aims to serve as a comprehensive platform for the dissemination of the latest research and advancements in the identification and validation of novel cancer biomarkers. We aim to explore not only the molecular intricacies of these markers but also their clinical applications and potential to shape personalized therapeutic strategies. Specific areas of focus include, but are not limited to: Novel genetic, epigenetic, proteomic, and metabolic markers; Technological advancements in biomarker discovery; Bioinformatics approaches in data mining for potential biomarkers; Clinical utility and validation studies; Implications for personalized medicine and therapy adjustments based on biomarker profiles. We intend for this Special Issue to bring together a multidisciplinary cohort of researchers, clinicians, and scholars, shedding light on the future of personalized oncology through the lens of biomarker discovery.

Guest Editors

Prof. Dr. Daniela Calina
Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania

Dr. Luca Falzone
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy

Deadline for manuscript submissions

15 June 2025

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

MDPI